BioSpace News Archive

AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 163,500 shares of the company’s common stock to five new employees as inducement awards, consisting of 30,500 shares granted under the company’s 2019 Inducement Plan and 133,000 shares granted under the company’s 2020 Inducement Plan.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that its Board of Directors has authorized a new share repurchase program under which the Company may repurchase up to $150 million of its outstanding shares of common stock through December 2022.

- BT7480, the lead Bicycle tumor-targeted immune cell agonist, presented at AACR Annual Meeting 2021 “New Drugs on the Horizon” session; remains on-track for 2H'21 clinical trial start - Achieved significant recent progress across pipeline of Bicycle ®-based therapies beyond oncology

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced it will publish first quarter 2021 financial results and provide a business update on Thursday, May 13, 2021.

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Company’s CEO Dr. Pnina Fishman will present at Benzinga’s Global SmallCap Conference on Thursday, May 13, 2021 at 11:10 a.m. ET on the Transformative Healthcare track.

- Viralym-M pivotal trial in virus-associated hemorrhagic cystitis continues to progress enrollment - Viralym-M proof-of-concept studies in multi-virus prevention in stem cell transplant and BK viremia in kidney transplant continue to progress with initial data expected 4Q21 - Additional Viralym-M pivotal and proof-of-concept clinical trials expected to initiate in 2H21

Lexaria Bioscience Corp. a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs.

Dyno Therapeutics, Inc. , a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced a $100 million Series A financing led by Andreessen Horowitz, with participation from a select syndicate of new investors

Recently Announced Phase 3 INVIGORATE Clinical Trial Results Indicated Statistically Significant Activity of Reproxalap in Ocular Itching and Redness Associated with Allergic Conjunctivitis Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Trials of Reproxalap in Dry Eye Disease Expected in the Second Half of 2021

- 1Q21 total net revenue increased to $19.9 million - - 1Q21 total net product revenue increased 60% to $19.6 million compared to 1Q20 - - ANNOVERA prescriptions continue to grow with increasing consumer support and acceptance - - Further strengthened ANNOVERA® patent family through June 2039 –